Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on March 23, 2020, reporting events that occurred on March 20, 2020. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes.
Material Changes
The Board of Directors appointed Paul Biondi as a Class III director, replacing Noubar B. Afeyan, Ph.D., who resigned on the same date. Mr. Biondi was appointed to serve on the Compensation Committee.
Compensatory Arrangements and Governance
- Annual Retainer: $35,000 for board service.
- Committee Retainer: $5,000 for service on the Compensation Committee.
- Equity Award: Initial option to purchase 30,000 shares of common stock.
- Exercise Price: $3.10 per share (closing price on the grant date).
- Vesting Schedule: Equal installments over four years, subject to continued service.
- Indemnification: Mr. Biondi entered into the Company's standard indemnification agreement for directors and officers.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the standard disclosure of the director appointment.
Key Facts for Investor Verification
- Confirmation of Noubar B. Afeyan's resignation and the effective date of Paul Biondi's appointment.
- Verification of the 30,000 share option grant and its $3.10 exercise price.
- Review of the Compensation Committee's composition following this appointment.
- Assessment of any potential conflicts of interest or related party transactions associated with the new director.